Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $340
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice TargetHot
Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $340.
Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $340.